Literature DB >> 526013

In vitro activity of three tetracycline antibiotics against Acinetobacter calcoaceticus subsp. anitratus.

J V Crues, B E Murray, R C Moellering.   

Abstract

The in vitro activity of three tetracycline antibiotics against 127 strains of Acinetobacter calcoaceticus (Herella vaginicola) were compared. Almost all strains were susceptible to minocycline and doxycycline, whereas most strains were resistant to tetracycline.

Entities:  

Mesh:

Substances:

Year:  1979        PMID: 526013      PMCID: PMC352932          DOI: 10.1128/AAC.16.5.690

Source DB:  PubMed          Journal:  Antimicrob Agents Chemother        ISSN: 0066-4804            Impact factor:   5.191


  10 in total

1.  In vitro synergism between carbenicillin and aminoglycosidic aminocyclitols against Acinetobacter calcoaceticus var. anitratus.

Authors:  R H Glew; R C Moellering; K R Buettner
Journal:  Antimicrob Agents Chemother       Date:  1977-06       Impact factor: 5.191

2.  Resistance to gentamicin, tobramycin and amikacin among clinical isolates of bacteria.

Authors:  R C Moellering; C Wennersten; L J Kunz; J W Poitras
Journal:  Am J Med       Date:  1977-06       Impact factor: 4.965

3.  Susceptibility of common pathogenic bacteria to seven tetracycline antibiotics in vitro.

Authors:  N H Steigbigel; C W Reed; M Finland
Journal:  Am J Med Sci       Date:  1968-03       Impact factor: 2.378

4.  Antibiotic susceptibility testing by a standardized single disk method.

Authors:  A W Bauer; W M Kirby; J C Sherris; M Turck
Journal:  Am J Clin Pathol       Date:  1966-04       Impact factor: 2.493

5.  Activity of minocycline against Acinetobacter calcoaceticus var. anitratus (syn. Herellea vaginicola) and Serratia marcescens.

Authors:  E G Maderazo; R Quintiliani; R C Tilton; R Bartlett; N C Joyce; V T Andriole
Journal:  Antimicrob Agents Chemother       Date:  1975-07       Impact factor: 5.191

6.  Side effects of minocycline: different dosage regimens.

Authors:  D W Gump; T Ashikaga; T J Fink; A M Radin
Journal:  Antimicrob Agents Chemother       Date:  1977-11       Impact factor: 5.191

7.  Pharmacokinetics of minocycline in renal failure.

Authors:  P G Welling; W R Shaw; S J Uman; F L Tse; W A Craig
Journal:  Antimicrob Agents Chemother       Date:  1975-11       Impact factor: 5.191

8.  In vitro antibacterial activity of minocycline and effect of agar medium utilized in its susceptibility testing.

Authors:  J A Washington; P K Yu; W J Martin
Journal:  Appl Microbiol       Date:  1970-02

9.  Aminoglycoside-modifying enzymes among clinical isolates of Acinetobacter calcoaceticus subsp. anitratus (Herellea vaginicola): explanation for high-level aminoglycoside resistance.

Authors:  B E Murray; R C Moellering
Journal:  Antimicrob Agents Chemother       Date:  1979-02       Impact factor: 5.191

10.  Infections with Acinetobacter calcoaceticus (Herellea vaginicola): clinical and laboratory studies.

Authors:  R H Glew; R C Moellering; L J Kunz
Journal:  Medicine (Baltimore)       Date:  1977-03       Impact factor: 1.889

  10 in total
  5 in total

1.  Antimicrobial drug susceptibility of clinical isolates of Acinetobacter species (A. baumannii, A. haemolyticus, genospecies 3, and genospecies 6).

Authors:  W H Traub; M Spohr
Journal:  Antimicrob Agents Chemother       Date:  1989-09       Impact factor: 5.191

2.  Community-acquired bacteremic Acinetobacter calcoaceticus var. anitratus pneumonia.

Authors:  H Westh; J Terp
Journal:  Infection       Date:  1988 Sep-Oct       Impact factor: 3.553

3.  Acinetobacter exposure keratitis.

Authors:  A Marcovich; S Levartovsky
Journal:  Br J Ophthalmol       Date:  1994-06       Impact factor: 4.638

4.  Bacteriuria caused by Acinetobacter calcoaceticus biovars in a normal population and in general practice.

Authors:  S Hoffmann; C E Mabeck; R Vejlsgaard
Journal:  J Clin Microbiol       Date:  1982-09       Impact factor: 5.948

5.  Trauma-induced endophthalmitis caused by Acinetobacter anitratus.

Authors:  D B Mark; M W Gaynon
Journal:  Br J Ophthalmol       Date:  1983-02       Impact factor: 4.638

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.